Eupraxia Pharmaceuticals (EPRX) Operating Leases (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Operating Leases for 5 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases changed N/A year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (changed N/A YoY), while the FY2025 annual figure was $75910.0, up 5.64% from the prior year.
• Operating Leases improved to $1.8 million in Q1 2026 per EPRX's latest filing, from $75910.0 in the prior quarter.
• Across five years, Operating Leases topped out at $1.8 million in Q1 2026 and bottomed at $37848.0 in Q1 2024.
• Historically, Operating Leases has averaged $259750.6 across 5 years, with a median of $71859.0 in 2024.
• Annual changes were most pronounced in 2023 — Operating Leases gained 3.92% — and 2024, when it soared 34.78%.
• Eupraxia Pharmaceuticals' Operating Leases stood at $51303.0 in 2022, then rose by 3.92% to $53316.0 in 2023, then soared by 34.78% to $71859.0 in 2024, then grew by 5.64% to $75910.0 in 2025, then jumped by 2275.57% to $1.8 million in 2026.
• Business Quant data shows EPRX's Operating Leases at $1.8 million in Q1 2026, $75910.0 in Q4 2025, and $94467.0 in Q3 2025.